NCBI Logo
GEO Logo
   NCBI > GEO > Accession DisplayHelp Not logged in | LoginHelp
GEO help: Mouse over screen elements for information.
          Go
Series GSE13319 Query DataSets for GSE13319
Status Public on Aug 20, 2009
Title Comparison of Human and Rat Uterine Leiomyoma: Identification of a Dysregulated mTOR Pathway
Organisms Homo sapiens; Rattus norvegicus
Experiment type Expression profiling by array
Summary Uterine leiomyomata, or fibroids, are benign tumors of the uterine myometrium that significantly affect up to 30% of reproductive-age women. Despite being the primary cause of hysterectomy in the United States, accounting for up to 200,000 procedures annually, the etiology of leiomyoma remains largely unknown. Due to the lack of an effective medicinal therapy for these tumors, this disease continues to have a tremendous negative impact on women’s health. As a basis for understanding leiomyoma pathogenesis and identifying targets for pharmacotherapy, we conducted transcriptional profiling of leiomyoma and unaffected myometrium from humans and Eker rats, the best characterized preclinical model of leiomyoma. A global comparison of mRNA from leiomyoma versus myometrium in human and rat identified a highly significant overlap of dysregulated gene expression in leiomyoma. An unbiased pathway analysis using a method of gene set enrichment based on the Sigpathway algorithm detected the mammalian target of rapamycin (mTOR) pathway as one of the most highly upregulated pathways in both human and rat tumors. Activation of this pathway was confirmed in both human and rat leiomyomata at the protein level via Western. Inhibition of mTOR in female Eker rats with the rapamycin analog WAY-129327 for 2 weeks decreased mTOR signaling and cell proliferation in tumors, and treatment for 4 months significantly decreased tumor incidence, multiplicity and size. These results identify dysregulated mTOR signaling as a component of leiomyoma etiology across species and directly demonstrate the dependence of these tumors on mTOR signaling for growth in the Eker rat. Modulation of this pathway warrants additional investigation as a potential therapy for uterine leiomyoma.

Keywords: Disease State Analysis: Animal Model Validation
 
Overall design We analyzed 1-3 leiomyoma or normal myometrium biopsies from each 23 woman undergoing hysterectomy for the treatment of uterine fibroids. tment and compared it leiomyoma and normal myometrium from the Eker rat model of uterine fibroids (N=14-15)
 
Contributor(s) Jelinsky S
Citation(s) 19622772
Submission date Oct 23, 2008
Last update date Mar 25, 2019
Contact name Scott Jelinsky
E-mail(s) Scott.Jelinsky@pfizer.com
Phone 617-674-7272
Organization name Pfizer
Department Inflammation and Immunology
Lab Computational Precision Medicine
Street address 610 Main Street
City Cambridge
State/province MA
ZIP/Postal code 02139
Country USA
 
Platforms (2)
GPL570 [HG-U133_Plus_2] Affymetrix Human Genome U133 Plus 2.0 Array
GPL1355 [Rat230_2] Affymetrix Rat Genome 230 2.0 Array
Samples (106)
GSM336202 Human_Leiomyoma_Donor 1_Replicate_1
GSM336203 Human_Leiomyoma_Donor 1_Replicate_2
GSM336204 Human_Leiomyoma_Donor 1_Replicate_3
Relations
BioProject PRJNA109907

Download family Format
SOFT formatted family file(s) SOFTHelp
MINiML formatted family file(s) MINiMLHelp
Series Matrix File(s) TXTHelp

Supplementary file Size Download File type/resource
GSE13319_RAW.tar 712.0 Mb (http)(custom) TAR (of CEL)
Processed data included within Sample table

| NLM | NIH | GEO Help | Disclaimer | Accessibility |
NCBI Home NCBI Search NCBI SiteMap